Avalon GloboCare (NASDAQ: AVCO) Enters Definitive Agreement To Acquire Hebei Senlang Biotech

July 19, 2021

Avalon GloboCare (NASDAQ: AVCO) has signed a definitive agreement to purchases PRC limited liability firm Hebei Senlang Biotech in an all-stock transaction. Avalon to acquire SenlangBio Currently, SenlangBio is the most considerable cell therapy firm in North China regarding the depth and breadth of clinical development programs, bio-manufacturing scale, and pre-clinical studies. Its core tech platforms include allogeneic CAR Gamma Delta T-cells, armored tumor-infiltrating lymphocytes, and chimeric antigen receptor T-cells….